<DOC>
	<DOCNO>NCT02450149</DOCNO>
	<brief_summary>This pilot study sorafenib patient BRAF Mutation Refractory Solid Tumors . This study single-arm , pilot study sorafenib patient Refractory Solid Tumors harbor BRAF Mutation Sorafenib 400 mg administer orally twice day 28 day . To investigate efficacy sorafenib patient Refractory Solid Tumors harbor BRAF Mutation .</brief_summary>
	<brief_title>Single-arm Study Evaluate Safety Efficacy Sorafenib , Subjects With BRAF Mutation Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Provision fully inform consent prior study specific procedure . 2 . Patients must ≥20 year age . 3 . BRAF mutation Refractory Solid Tumors recur progress follow standard therapy , respond standard therapy , standard therapy . 4 . ECOG performance status 02 . 5 . Have measurable evaluate disease base RECIST1.1 . determine investigator . 6 . Adequate Organ Function Laboratory Values Absolute neutrophil count ≥ 1.5 x 109/L , Hemoglobin ≥ 9g/dL , Platelets ≥ 100 x 109/L bilirubin ≤ 1.5 x upper limit normal AST/ALT ≤ 2.5 x upper limit normal ( 5.0 X upper limit normal , subject liver metastasis ) creatinine ≤1.5 x UNL 7 . Patients childbearing potential use adequate contraceptive measure ( two form highly reliable method ) breast feed must negative pregnancy test prior start dose . 8 . Adequate heart function . 1 . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease ≤3 year . 2 . Has know active central nervous system ( CNS ) metastases . 3 . Has active infection require systemic therapy . 4 . Pregnancy breast feed 5 . Patients cardiac problem . 6 . Any previous treatment sorafenib</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>